Stroke patients or others with neurological injury are turning to the rehabilitation powers of robots with artificial intelligence that help people regain previously lost mobility. BIONIK Laboratories, a global health care company with an office in Watertown, develops robotic "InMotion" systems for the arm, hand and wrist. The FDA-cleared products, which are used in hospitals and rehabilitation facilities, work seamlessly by guiding patients with the help of a physical therapist through various movement activities displayed on a monitor. Once the patient has a hand and arm in the InMotion device, robotic therapy takes over, using artificial intelligence to provide the patient as much assistance as needed to work through a series of movements aimed at regaining the patient's mobility. Dr. Eric Dusseux, CEO of BIONIK, said, "We have demonstrated that by using robotic therapy, you can heal faster and better than any conventional therapy. Dusseux said the autonomy and self-esteem experienced by patients using the robots "is exactly what you need when you're a patient suffering from neurological disease." The system even has therapies styled like video games for younger patients. A typical session with the robot may last 30 minutes to an hour, with thousands of people using the 250 systems that have been implemented in over 20 countries. Dusseux said the artificial intelligence data is processed to help patients and doctors get a good idea of progress, often boosting the spirits of those who are frustrated with their limited mobility. "You can imagine the support for the first time after your stroke.

You could be forgiven for thinking that AI will soon replace human physicians based on headlines such as "The AI Doctor Will See You Now," "Your Future Doctor May Not Be Human," and "This AI Just Beat Human Doctors on a Clinical Exam." But experts say the reality is more of a collaboration than an ousting: Patients could soon find their lives partly in the hands of AI services working alongside human clinicians. There is no shortage of optimism about AI in the medical community. But many also caution the hype surrounding AI has yet to be realized in real clinical settings. There are also different visions for how AI services could make the biggest impact.

April last year, a medical device powered by artificial intelligence (AI) received approval from the US Food and Drug Administration (USFDA), marking a historic moment in healthcare globally. The IDx-DR, a software algorithm that uses AI to analyse images of the eye using a camera, achieved an 87.4% accuracy rate while detecting'more than mild' diabetic retinopathy, a condition where high blood sugar levels damage the blood vessels in the retina. For IT services firms, which are already developing AI and machine language (ML) tools for other uses and industries, extending AI and ML capabilities to healthcare is a fairly non-complex process, and comes with a large upside. Rather than doing it entirely on their own though, these companies are partnering hospital chains and niche players in the field to acquire the required domain expertise. For instance, Japanese technology firm NTT DATA Services tied up with Pune's Deenanath Mangeshkar Hospital last year to use an AI-based solution to diagnose emphysema, a chronic condition of the lungs.

IDx, a Coralville-based med technology firm, is giving the world a glimpse into what eye health care might look like in the future. IDx-DR, an autonomous artificial intelligence diagnostic system developed by Dr. Michael Abramoff to detect diabetic retinopathy, gained approval in 2018 from the U.S. Food and Drug Administration. The technology is to be used in health care settings patients already visit, such as their primary care physician's office, to catch the disease before it causes permanent damage. "The early detection of this disease is important. We're reducing the burden on patients by making it easier to access testing," said Ben Clark, president and chief operating officer of IDx. "Diabetic retinopathy is the leading cause of preventable blindness in the United States," he said.

In April last year, a medical device powered by artificial intelligence (AI) received approval from the US Food and Drug Administration (USFDA), marking a historic moment in healthcare globally. The IDx-DR, a software algorithm that uses AI to analyse images of the eye using a camera, achieved an 87.4% accuracy rate while detecting'more than mild' diabetic retinopathy, a condition where high blood sugar levels damage the blood vessels in the retina. For IT services firms, which are already developing AI and machine language (ML) tools for other uses and industries, extending AI and ML capabilities to healthcare is a fairly non-complex process, and comes with a large upside. Rather than doing it entirely on their own though, these companies are partnering hospital chains and niche players in the field to acquire the required domain expertise. For instance, Japanese technology firm NTT DATA Services tied up with Pune's Deenanath Mangeshkar Hospital last year to use an AI-based solution to diagnose emphysema, a chronic condition of the lungs.

You could be forgiven for thinking that A.I. will soon replace human physicians based on headlines such as "The A.I. Doctor Will See You Now," "Your Future Doctor May Not Be Human," and "This A.I. Just Beat Human Doctors on a Clinical Exam." But experts say the reality is more of a collaboration than an ousting: Patients could soon find their lives partly in the hands of A.I. services working alongside human clinicians. There is no shortage of optimism about A.I. in the medical community. But many also caution the hype surrounding A.I. has yet to be realized in real clinical settings. There are also different visions for how A.I. services could make the biggest impact.

Many hospitals are facing trouble with low compliance rates of usage reporting inside the operating room, inaccurate charge capture, meeting FDA requirements regarding digital updates to the patient's file and countless coding errors. These problems all have the potential to cause a financial loss. Hospitals use advanced software solutions to improve processes, streamline workflow and optimize resources. By 2026, the healthcare information industry is forecasted to grow by 8.2%. Yet while these solutions specialize in data management and analyze procurement processes, they are not suited to the specific needs and work conditions in hospital operating rooms, resulting in deficient data collection.

You could be forgiven for thinking that AI will soon replace human physicians based on headlines such as "The AI Doctor Will See You Now," "Your Future Doctor May Not Be Human," and "This AI Just Beat Human Doctors on a Clinical Exam." But experts say the reality is more of a collaboration than an ousting: Patients could soon find their lives partly in the hands of AI services working alongside human clinicians. "In the same way that technologies can close disparities, they can exacerbate disparities." There is no shortage of optimism about AI in the medical community. But many also caution the hype surrounding AI has yet to be realized in real clinical settings. There are also different visions for how AI services could make the biggest impact.

Elon Musk announced late Tuesday night that the final goal of Neuralink, his brain-machine interface startup, is to allow humans to "achieve a symbiosis with artificial intelligence," and that by "merging with AI," humans will be able to keep up with AI. Musk plans to begin human trials on an early version of Neuralink intended to treat brain injuries next year. "Ultimately we can do a full brain machine interface," Musk said in an announcement that was widely livestreamed. "This is going to sound pretty weird. Ultimately we can achieve a symbiosis with artificial intelligence. This is not a mandatory thing, this is something you can choose to have if you want. This is going to be really important at a civilization-level scale. Even in a benign AI scenario, we will be left behind. With a high-bandwidth brain machine interface we can go along for the ride and have the option of merging with AI." Musk has become famous for his moonshot projects, his lofty promises, his quick temper on Twitter, and his various plans for society that don't include input from the rest of us.

Elon Musk said startup Neuralink, which aims to build a scalable implant to connect human brains with computers, has already implanted chips in rats and plans to test its brain-machine interface in humans within two years, with a long-term goal of people "merging with AI." Brain-machine interfaces have been around for awhile. Some of the earliest success with the technology include Brown University's BrainGate, which first enabled a paralyzed person to control a computer cursor in 2006. Since then a variety of research groups and companies, including the University of Pittsburgh Medical Center and DARPA-backed Synchron, have been working on similar devices. There are two basic approaches: You can do it invasively, creating an interface with an implant that directly touches the brain, or you can do it non-invasively, usually by electrodes placed near the skin. Neuralink, says Musk, is going to go the invasive route.